Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jordi Rodon

Showing results (201-210 of 247) with videos related to

Pageof 25
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 27, 2021
A Phase I Dose-Escalation Study to Evaluate the Safety and Tolerability of Evofosfamide in Combination with Ipilimumab in Advanced Solid MalignanciesAparna Hegde, Priyamvada Jayaprakash, Coline A Couillault, et al.
Journal of Hematology & Oncology|June 6, 2025
Results of a phase 1/2 study of sacituzumab tirumotecan in patients with unresectable locally advanced or metastatic solid tumors refractory to standard therapiesQuchang Ouyang, Jordi Rodon, Yan Liang, et al.
Nature Medicine|April 10, 2025
Sacituzumab tirumotecan in advanced non-small-cell lung cancer with or without EGFR mutations: phase 1/2 and phase 2 trialsShen Zhao, Ying Cheng, Qiming Wang, et al.
Scientific Reports|January 29, 2021
SARS-CoV-2 infection elicits a rapid neutralizing antibody response that correlates with disease severityBenjamin Trinité, Ferran Tarrés-Freixas, Jordi Rodon, et al.
European Journal of Cancer (Oxford, England : 1990)|August 13, 2021
Phase I prognostic online (PIPO): A web tool to improve patient selection for oncology early phase clinical trialsIgnacio Matos, Guillermo Villacampa, Cinta Hierro, et al.
Cancer|April 5, 2023
Phase 1b study of combined selinexor and eribulin for the treatment of advanced solid tumors and triple-negative breast cancerBlessie Elizabeth Nelson, Sadia Saleem, Senthil Damodaran, et al.
Cancer Research Communications|September 15, 2023
A Phase I Study of the Pan-Notch Inhibitor CB-103 for Patients with Advanced Adenoid Cystic Carcinoma and Other TumorsGlenn J Hanna, Anastasios Stathis, Elena Lopez-Miranda, et al.
Cancer Discovery|March 26, 2026
Comprehensive Genomic and Transcriptomic Analysis to Guide Therapy for Patients with Metastatic Solid TumorsBurak Uzunparmak, Fei Su, Amber Johnson, et al.
Cancer|February 7, 2025
Olaparib in treatment-refractory isocitrate dehydrogenase 1 (IDH1)- and IDH2-mutant cholangiocarcinoma: Safety and antitumor activity from the phase 2 National Cancer Institute 10129 trialMichael Cecchini, Mary Jo Pilat, Nataliya Uboha, et al.
JCO Precision Oncology|February 6, 2025
Phase II Study of Copanlisib in Patients With PTEN Loss: Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols Z1G and Z1HMohamed A Gouda, Zihan Wei, Jordi Rodon, et al.
Pageof 25

Showing results (201-210 of 247) with videos related to

Sort By:
Pageof 25
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 27, 2021
A Phase I Dose-Escalation Study to Evaluate the Safety and Tolerability of Evofosfamide in Combination with Ipilimumab in Advanced Solid MalignanciesAparna Hegde, Priyamvada Jayaprakash, Coline A Couillault, et al.
Journal of Hematology & Oncology|June 6, 2025
Results of a phase 1/2 study of sacituzumab tirumotecan in patients with unresectable locally advanced or metastatic solid tumors refractory to standard therapiesQuchang Ouyang, Jordi Rodon, Yan Liang, et al.
Nature Medicine|April 10, 2025
Sacituzumab tirumotecan in advanced non-small-cell lung cancer with or without EGFR mutations: phase 1/2 and phase 2 trialsShen Zhao, Ying Cheng, Qiming Wang, et al.
Scientific Reports|January 29, 2021
SARS-CoV-2 infection elicits a rapid neutralizing antibody response that correlates with disease severityBenjamin Trinité, Ferran Tarrés-Freixas, Jordi Rodon, et al.
European Journal of Cancer (Oxford, England : 1990)|August 13, 2021
Phase I prognostic online (PIPO): A web tool to improve patient selection for oncology early phase clinical trialsIgnacio Matos, Guillermo Villacampa, Cinta Hierro, et al.
Cancer|April 5, 2023
Phase 1b study of combined selinexor and eribulin for the treatment of advanced solid tumors and triple-negative breast cancerBlessie Elizabeth Nelson, Sadia Saleem, Senthil Damodaran, et al.
Cancer Research Communications|September 15, 2023
A Phase I Study of the Pan-Notch Inhibitor CB-103 for Patients with Advanced Adenoid Cystic Carcinoma and Other TumorsGlenn J Hanna, Anastasios Stathis, Elena Lopez-Miranda, et al.
Cancer Discovery|March 26, 2026
Comprehensive Genomic and Transcriptomic Analysis to Guide Therapy for Patients with Metastatic Solid TumorsBurak Uzunparmak, Fei Su, Amber Johnson, et al.
Cancer|February 7, 2025
Olaparib in treatment-refractory isocitrate dehydrogenase 1 (IDH1)- and IDH2-mutant cholangiocarcinoma: Safety and antitumor activity from the phase 2 National Cancer Institute 10129 trialMichael Cecchini, Mary Jo Pilat, Nataliya Uboha, et al.
JCO Precision Oncology|February 6, 2025
Phase II Study of Copanlisib in Patients With PTEN Loss: Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols Z1G and Z1HMohamed A Gouda, Zihan Wei, Jordi Rodon, et al.
Pageof 25